These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

920 related articles for article (PubMed ID: 33302685)

  • 1. Treatment of refractory gout with TNF-α antagonist etanercept combined with febuxostat.
    Zhang Y; Pan R; Xu Y; Zhao Y
    Ann Palliat Med; 2020 Nov; 9(6):4332-4338. PubMed ID: 33302685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
    Lei Y; Cui TJ; Wang XH; Zhang XM; Tang C; Zheng ZH
    Front Immunol; 2022; 13():1045982. PubMed ID: 36505444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
    Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
    Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
    Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
    Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.
    Juge PA; Truchetet ME; Pillebout E; Ottaviani S; Vigneau C; Loustau C; Cornec D; Pascart T; Snanoudj R; Bailly F; Cornec-Le Gall E; Schaeverbeke T; Saraux A; Dieudé P; Flipo RM; Richette P; Lioté F; Bardin T; Chalès G; Ea HK
    Joint Bone Spine; 2017 Oct; 84(5):595-598. PubMed ID: 27825577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of gout secondary to primary myelofibrosis].
    Ji LL; Hao YJ; Zhang ZL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1117-1119. PubMed ID: 30562793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.
    Meng J; Li Y; Yuan X; Lu Y
    Rheumatol Int; 2017 Feb; 37(2):299-303. PubMed ID: 27878622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting.
    Yu J; Qiu Q; Liang L; Yang X; Xu H
    Mod Rheumatol; 2018 Mar; 28(2):339-344. PubMed ID: 28485997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
    Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
    Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
    Saag KG; Becker MA; Whelton A; Hunt B; Castillo M; Kisfalvi K; Gunawardhana L
    Arthritis Rheumatol; 2019 Jan; 71(1):143-153. PubMed ID: 30073793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.